Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2013, Article ID 102120, 8 pages
http://dx.doi.org/10.1155/2013/102120
Clinical Study

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus

12nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens, Greece
22nd Department of Pediatrics, Diabetes & Metabolism Clinic, University of Athens, “P&A Kyriakou” Children's Hospital, Athens, Greece
3Radiology Department, “P&A Kyriakou” Children's Hospital, Athens, Greece
4Hormonal Laboratory, University of Athens, Aretaieio Hospital, Athens, Greece
5Department of Therapeutics, University of Athens, Alexandra Hospital, Athens, Greece

Received 25 June 2013; Revised 31 August 2013; Accepted 3 September 2013

Academic Editor: Faustino R. Pérez-López

Copyright © 2013 Irene Lambrinoudaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Irene Lambrinoudaki, Emmanouil Tsouvalas, Marina Vakaki, et al., “Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus,” International Journal of Endocrinology, vol. 2013, Article ID 102120, 8 pages, 2013. https://doi.org/10.1155/2013/102120.